Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
trials in parallel for Haduvio in IPF-related chronic cough: a global 52-week study (~ 300 patients ) starting in Q2 2026 with a 24-week primary readout, and a smaller confirmatory global trial (~ 130 patients ) starting in H2 2026 with a 12-week primary endpoint. Trevi plans a phase IIb dose-ranging trial in refractory chronic cough beginning in Q2 2026 , testing three doses plus placebo with a sample-size re-estimation and exploration of lower or once-daily dosing. The company ended 2025 with about $188 million in cash, providing an expected runway into to fund top-line readouts from the 12-week IPF trial and phase IIb RCC/non-IPF studies, but does not cover the 24-week readout from the 52-week IPF trial. Interested in Trevi Therapeutics, Inc.? Here are five stocks we like better. MarketBeat's Top 5 Rated Small-Cap Stocks Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a p
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- 3/9/26 - Form 8-K
- TRVI's page on the SEC website